World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
103
Citations
35498
World Ranking
648
National Ranking
378

Medicine

D-Index
103
Citations
35538
World Ranking
7417
National Ranking
3877

Robert Yarchoan publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Robert Yarchoan sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 420 publications — 83rd percentile

83% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Robert Yarchoan D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Robert Yarchoan sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 103 D-Index — 87th percentile

87% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Research.com Recognitions

  • 1993 - Fellow of the American Association for the Advancement of Science (AAAS)

Overview

Robert Yarchoan is affiliated with the National Institutes of Health in the United States. Their research primarily intersects the fields of medicine, with a significant focus on oncology, pathology and forensic medicine, infectious diseases, epidemiology, and physiology.

The scope of their work extensively covers viral-associated cancers and disorders, lymphoma diagnosis and treatment, histiocytic disorders and treatments, cytomegalovirus and herpesvirus research, CNS lymphoma diagnosis and treatment, chronic lymphocytic leukemia research, and polyomavirus and related diseases.

Among the recent research papers associated with Robert Yarchoan are the following:

  • A small molecule compound with an indole moiety inhibits the main protease of SARS-CoV-2 and blocks virus replication, 2021, Nature Communications
  • Pembrolizumab induces HIV latency reversal in people living with HIV and cancer on antiretroviral therapy, 2022, Science Translational Medicine
  • GRL-0920, an Indole Chloropyridinyl Ester, Completely Blocks SARS-CoV-2 Infection, 2020, mBio
  • Genetic subgroups inform on pathobiology in adult and pediatric Burkitt lymphoma, 2022, Blood
  • Analysis of Ugandan cervical carcinomas identifies human papillomavirus clade-specific epigenome and transcriptome landscapes, 2020, Nature Genetics

Frequent coauthors collaborating with Robert Yarchoan include:

  • Ramya Ramaswami (47 joint publications)
  • Kathryn Lurain (45 joint publications)
  • Thomas S. Uldrick (30 joint publications)
  • David A. Davis (20 joint publications)
  • Denise Whitby (20 joint publications)

Robert Yarchoan has published frequently in the following venues:

  • Blood (8 publications)
  • Journal of Clinical Oncology (7 publications)
  • bioRxiv (Cold Spring Harbor Laboratory) (5 publications)
  • PLoS Pathogens (4 publications)
  • AIDS (4 publications)

In recognition of their contributions, Robert Yarchoan was named a Fellow of the American Association for the Advancement of Science (AAAS) in 1993.

Best Publications

  • Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro.

    L A Rubin;C C Kurman;M E Fritz;W E Biddison

  • Molecular targets for AIDS therapy

    Hiroaki Mitsuya;Robert Yarchoan;Samuel Broder

  • ADMINISTRATION OF 3'-AZIDO-3'-DEOXYTHYMIDINE, AN INHIBITOR OF HTLV-III/LAV REPLICATION, TO PATIENTS WITH AIDS OR AIDS-RELATED COMPLEX

    Robert Yarchoan;Kent J. Weinhold;H. Kim Lyerly;Edward Gelmann

  • Cancer Burden in the HIV-Infected Population in the United States

    Meredith S. Shiels;Ruth M. Pfeiffer;Mitchell H. Gail;H. Irene Hall

  • CD4 counts as predictors of opportunistic pneumonias in human immunodeficiency virus (HIV) infection.

    H Masur;F P Ognibene;R Yarchoan;J H Shelhamer

  • PHASE I STUDIES OF 2',3'-DIDEOXYCYTIDINE IN SEVERE HUMAN IMMUNODEFICIENCY VIRUS INFECTION AS A SINGLE AGENT AND ALTERNATING WITH ZIDOVUDINE (AZT)

    Robert Yarchoan;Rose V. Thomas;Jean Pierre Allain;Nanette Mcatee

  • In vivo activity against HIV and favorable toxicity profile of 2',3'-dideoxyinosine

    Robert Yarchoan;Hiroaki Mitsuya;Rose V. Thomas;James M. Pluda

  • Suramin protection of T cells in vitro against infectivity and cytopathic effect of HTLV-III.

    Hiroaki Mitsuya;Mikulas Popovic;Robert Yarchoan;Shuzo Matsushita

  • Plasma and cerebrospinal fluid pharmacokinetics of 3'-azido-3'-deoxythymidine: a novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases.

    Raymond W Klecker;Jerry M Collins;Robert Yarchoan;Rose Thomas

  • A potential role for interleukin-7 in T-cell homeostasis

    Terry J. Fry;Elizabeth Connick;Judith Falloon;Michael Marcel Lederman

  • HIV-Associated Cancers and Related Diseases

    Robert Yarchoan;Thomas S. Uldrick

  • Clinical pharmacology of 3'-azido-2',3'-dideoxythymidine (zidovudine) and related dideoxynucleosides.

    Robert Yarchoan;Hiroaki Mitsuya;Charles E. Myers;Samuel Broder

  • Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides.

    T Shirasaka;M F Kavlick;T Ueno;W Y Gao

  • Response of human-immunodeficiency-virus-associated neurological disease to 3'-azido-3'-deoxythymidine.

    Robert Yarchoan;Robert Yarchoan;Pim Brouwers;Pim Brouwers;A. Robert Spitzer;A. Robert Spitzer;Jordan Grafman;Jordan Grafman;Jordan Grafman

  • Differential Gene Up-Regulation by Hypoxia-Inducible Factor-1α and Hypoxia-Inducible Factor-2α in HEK293T Cells

    Victoria Wang;David A. Davis;Muzammel Haque;L. Eric Huang

  • Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology

    Richard F. Little;Stefania Pittaluga;Nicole Grant;Seth M. Steinberg

  • Replication of human immunodeficiency virus in monocytes. Granulocyte/macrophage colony-stimulating factor (GM-CSF) potentiates viral production yet enhances the antiviral effect mediated by 3'-azido-2'3'-dideoxythymidine (AZT) and other dideoxynucleoside congeners of thymidine.

    C.-F. Perno;R. Yarchoan;D. A. Cooney;N. R. Hartman

  • Development of Non-Hodgkin Lymphoma in a Cohort of Patients with Severe Human Immunodeficiency Virus (HIV) Infection on Long-Term Antiretroviral Therapy

    James M. Pluda;Robert Yarchoan;Elaine S. Jaffe;Irwin M. Feuerstein

  • Activity of Thalidomide in AIDS-Related Kaposi’s Sarcoma

    Richard F. Little;Kathleen M. Wyvill;James M. Pluda;Lauri Welles

  • Involvement of interleukin-10 (IL-10) and viral IL-6 in the spontaneous growth of Kaposi's sarcoma herpesvirus-associated infected primary effusion lymphoma cells.

    Karen D. Jones;Yoshiyasu Aoki;Yoshiyasu Aoki;Yoshiyasu Aoki;Yuan Chang;Yuan Chang;Yuan Chang;Patrick S. Moore;Patrick S. Moore;Patrick S. Moore

  • Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection

    PA Pizzo;J Eddy;J Falloon;FM Balis

Frequent Co-Authors

Seth M. Steinberg
Seth M. Steinberg National Institutes of Health
Samuel Broder
Samuel Broder Precision BioSciences
Giovanna Tosato
Giovanna Tosato National Institutes of Health
Stefania Pittaluga
Stefania Pittaluga National Institutes of Health
Denise Whitby
Denise Whitby Frederick National Laboratory for Cancer Research
Hiroaki Mitsuya
Hiroaki Mitsuya Kumamoto University
William D. Figg
William D. Figg National Institutes of Health
Elaine S. Jaffe
Elaine S. Jaffe National Institutes of Health
Wyndham H. Wilson
Wyndham H. Wilson National Institutes of Health
David Venzon
David Venzon National Institutes of Health

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a career in immunology often requires strong foundational knowledge in healthcare and biology. For those interested in advancing their qualifications, there are various online programs tailored to meet different professional needs. For example, nurses looking to expand their scope can explore accelerated RN to NP programs that offer a faster route to becoming a nurse practitioner.

Additionally, registered nurses who began their careers without a traditional nursing degree might find online RN programs for non-nurses particularly beneficial. These programs bridge the gap by providing essential clinical and theoretical training remotely, which is ideal for working professionals.

For those aiming to specialize further, acute care certification for FNP is a valuable credential that enables Family Nurse Practitioners to handle complex patient cases in acute settings. This specialization complements immunology-focused careers well, given the critical role of immune responses in intensive care.

Finally, prospective students looking for more accessible entry points into nursing may consider ABSN programs with high acceptance rates. These accelerated bachelor’s programs cater to career changers and offer a streamlined path into the nursing field, laying a solid foundation for advanced studies in immunology and related healthcare disciplines.

Best Scientists Citing Robert Yarchoan

Trending Scientists

Recently Published Articles